3
Announcements
Trials
Browse
Landscape
Phase
Phase NA
1
Phase 2
1
Status
Recruiting
2
Sponsor Class
OTHER
2
Study Type
Interventional
2
Sponsor
Cancer Type
Sarcoma
2
Breast
1
Conditions
Sarcoma
6
Triple Negative Breast Neoplasms
2
Pathologic Complete Response
2
Osteosarcoma
2
Hemangiosarcoma
2
Breast Neoplasms
2
Bone Neoplasms
2
Urinary Bladder Neoplasms
1
Stomach Neoplasms
1
Sarcoma, Ewing
1
Recurrence
1
Rectal Neoplasms
1
Patient Compliance
1
Pancreatic Neoplasms
1
Ovarian Neoplasms
1
Neoplasms
1
Myelodysplastic Syndromes
1
Melanoma
1
Locally Advanced or Metastatic Infantile Fibrosarcoma Harboring an NTRK Gene Fusion
1
Leukemia, Myeloid, Acute
1
Leiomyosarcoma
1
Histiocytoma, Malignant Fibrous
1
Esophageal Neoplasms
1
Endometrial Clear Cell Adenocarcinoma
1
Disease Progression
1
Colonic Neoplasms
1
Chondrosarcoma
1
Carcinoma, Renal Cell
1
Carcinoma, Non-Small-Cell Lung
1
Interventions
Standard of Care
2
zanidatamab
1
veliparib
1
tucatinib
1
trilaciclib
1
trebananib
1
trastuzumab duocarmazine
1
talazoparib
1
sarilumab
1
regorafenib
1
pexidartinib
1
pertuzumab
1
pembrolizumab
1
patritumab
1
olaparib
1
niraparib
1
neratinib
1
ganitumab
1
durvalumab
1
dostarlimab
1
cemiplimab
1
abemaciclib
1
Trastuzumab
1
Transurethral Resection of Bladder
1
STA 9090
1
SGN-LIV1A
1
Paclitaxel
1
MK 2206
1
Letrozole
1
Lasofoxifene
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Pathologic Complete Response
×
Standard of Care
×
Sarcoma
×
Clear all
NCT01042379
2026-05-06
I-SPY
QuantumLeap Healthcare Collaborative
Phase 2
Recruiting
5,000 enrolled
NCT04055220
2026-02-17
REGOSTA
Centre Leon Berard
Phase NA
Recruiting
168 enrolled